CGT

top of page

Search

Illustration of immune cells targeting papilloma growths in the respiratory tract, representing new FDA-approved therapy for RRP.

Illustration of immune cells targeting papilloma growths in the respiratory tract, representing new FDA-approved therapy for RRP.

FDA Approves First Therapy for Recurrent Respiratory Papillomatosis

Published on: Precigen Investors The U.S. FDA has granted full approval to PAPZIMEOS (zopapogene imadenovec-drba), the first therapy for...

Regulatory & Compliance

Aug 16

ARM Sector Snapshot Q2 2025: Key Trends in Cell and Gene Therapy

ARM Sector Snapshot Q2 2025: Key Trends in Cell and Gene Therapy

ARM Sector Snapshot Q2 2025: Key Trends in Cell and Gene Therapy

Published on: Alliance for Regenerative Medicine The Alliance for Regenerative Medicine’s Q2 2025 Sector Snapshot showcases pivotal...

Aug 16

bottom of page